SHANGHAI and HONG
KONG, Nov. 5, 2024 /PRNewswire/ -- Antengene
Corporation Limited ("Antengene", SEHK: 6996.HK), a leading
innovative, commercial-stage global biopharmaceutical company
dedicated to discovering, developing and commercializing
first-in-class and/or best-in-class medicines for cancer, today
announced that it will present the latest data from two clinical
studies of selinexor in two Posters at the 2024 American Society of
Hematology Annual Meeting (ASH 2024), taking place on December 7-10, 2024, in San Diego, CA, the
United States.
Details on the Posters:
Title: Weekly
Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly
Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed
and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase
III Bench Study
Publication Number: 4748
Session: 654. Multiple Myeloma: Pharmacologic Therapies:
Poster III
Date: Monday, December 9,
2024
Time: 6:00 PM - 8:00 PM (Eastern
time)
7:00 AM - 9:00 AM, December
10, 2024 (Beijing time)
First Author: Dr. Jin Lu
(Peking University People's Hospital)
Corresponding Author: Dr. Jian
Hou (Ren Ji Hospital, Shanghai Jiao Tong University School
of Medicine)
Title: Selinexor Combined with Tislelizumab in Patients
with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R
ENKTL): Preliminary Results of Arm C, from a Multicenter,
Single-Arm, Phase I/II Study, Touch
Publication Number: 4448
Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas:
Clinical and Epidemiological: Poster III
Date: Monday, December 9,
2024
Time: 6:00 PM - 8:00 PM (Eastern
time)
7:00 AM - 9:00 AM, December
10, 2024 (Beijing time)
First Author: Dr. Rong Tao (Fudan University Shanghai Cancer
Center)
Corresponding Author: Dr. Huiqiang
Huang (Sun Yat-Sen University Cancer Center)
About XPOVIO®
(selinexor)
XPOVIO® is the
world's first approved orally-available, selective inhibitor of the
nuclear export protein XPO1. It offers a novel mechanism of
action, synergistic effects in combination regimens, fast onset of
action, and durable responses.
By blocking the nuclear export protein XPO1,
XPOVIO® can promote the
intranuclear accumulation and activation of tumor suppressor
proteins and growth regulating proteins, and down-regulate the
levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects
through three mechanistic pathways: 1) exerting antitumor effects
by inducing the intranuclear accumulation of tumor suppressor
proteins; 2) reducing the level of oncogenic proteins in the
cytoplasm by inducing the intranuclear accumulation of oncogenic
mRNAs; 3) restoring hormone sensitivity by activating the
glucocorticoid receptors (GR) pathway. To utilize its unique
mechanism of actions, XPOVIO® is being evaluated for use in
multiple combination regimens in a range of indications. At
present, Antengene is conducting multiple clinical studies of
XPOVIO® in the mainland
of China for the treatment of
relapsed/refractory hematologic malignancies and solid tumors (3 of
these studies are being jointly conducted by Antengene and
Karyopharm Therapeutics Inc. [Nasdaq:KPTI]).
About Antengene
Antengene Corporation Limited ("Antengene", SEHK:
6996.HK) is a leading commercial-stage R&D-driven global
biopharmaceutical company focused on the discovery, development,
manufacturing and commercialization of innovative
first-in-class/best-in-class therapeutics for the treatment of
hematologic malignancies and solid tumors, in realizing its vision
of "Treating Patients Beyond Borders".
Since 2017, Antengene has built a pipeline of 9 oncology assets
at various stages going from clinical to commercial, including 6
with global rights, and 3 with rights for the APAC region. To date,
Antengene has obtained 31 investigational new drug (IND) approvals
in the U.S. and Asia, and
submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for
XPOVIO® (selinexor)
already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand and Australia.
Forward-looking statements
The forward-looking statements made in this article relate only
to the events or information as of the date on which the statements
are made in this article. Except as required by law, we undertake
no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events
or otherwise, after the date on which the statements are made or to
reflect the occurrence of unanticipated events. You should read
this article completely and with the understanding that our actual
future results or performance may be materially different from what
we expect. In this article, statements of, or references to, our
intentions or those of any of our Directors or our Company are made
as of the date of this article. Any of these intentions may alter
in light of future development. For a further discussion of these
and other factors that could cause future results to differ
materially from any forward-looking statement, please see the other
risks and uncertainties described in the Company's Annual Report
for the year ended December 31, 2023,
and the documents subsequently submitted to the Hong Kong Stock
Exchange.
For more information, please contact:
Investor Contacts:
Donald Lung
E-mail: Donald.Lung@antengene.com
Mobile: +86 18420672158
PR Contacts:
Peter Qian
E-mail: Peter.Qian@antengene.com
Mobile: +86 13062747000
View original content to download
multimedia:https://www.prnewswire.com/news-releases/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential-clinical-breakthrough-at-ash-2024-302296438.html
SOURCE Antengene Corporation Limited